The FDA has granted Orphan Drug Designation to Tris Pharma’s TRN-257, an investigational once-nightly, low-sodium oxybate therapy for the treatment of idiopathic hypersomnia. The designation recognizes the potential for this formulation to reduce nocturnal treatment burdens while offering a lower-sodium alternative for patients requiring long-term care.
The EEG system features a 21-electrode setup and cloud connectivity to help clinics address staffing shortages and expand access to neurodiagnostics.
The transition is expected to reduce professional fees and potentially impact procedure volume.
Following the establishment of new CMS reimbursement codes for digital mental health treatments, the funding will support the commercial expansion of two prescription products.
The province will adopt permanent Daylight Saving Time, effective this month.
Tirzepatide copycats have implications for the safety of patients seeking treatment for obesity and obstructive sleep apnea.
The new center is part of a national expansion strategy using a capital-efficient affiliation model with existing sleep practices.
SMAPP aims to bridge education gaps with a ‘by APPs, for APPs’ training model designed to elevate patient care.
Earn sleep continuing education credits (CSTEs) from Sleep Review's July/August 2025 digital edition.